BioArctic AB (publ) (BRCTF)
| Market Cap | 1.70B |
| Revenue (ttm) | 23.25M |
| Net Income (ttm) | -16.00M |
| Shares Out | n/a |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 373 |
| Average Volume | 153 |
| Open | 19.00 |
| Previous Close | 18.48 |
| Day's Range | 19.00 - 19.00 |
| 52-Week Range | 12.94 - 24.80 |
| Beta | -0.67 |
| RSI | 56.10 |
| Earnings Date | May 21, 2025 |
About BioArctic AB
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company research and development of innovative biological drugs, such as antibodies, that address high unmet medical needs. Its therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, the company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, it develops lecanemab phase 3 clinical trial... [Read more]
News
The European Commission refers lecanemab decision to Appeal Committee
STOCKHOLM , April 1, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer the marketing authorisat...
BioArctic's partner Eisai presents sales simulation for Leqembi® at its annual press conference
STOCKHOLM , March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation [1] of potential future sales for Leqem...
BioArctic receives Orphan Drug Designation for exidavnemab the US
STOCKHOLM , March 17, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designati...
Therapeutic Goods Administration decides not to register lecanemab in Australia
STOCKHOLM, Sweden , March 3, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia ...
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU
STOCKHOLM , Feb. 28, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the Eu...
Leqembi® sales reaches €200 million - first sales milestone achieved
STOCKHOLM , Feb. 18, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has ...
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
STOCKHOLM , Jan. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM : BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supp...
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
STOCKHOLM , Jan. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Suppl...
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
STOCKHOLM , Jan. 13, 2025 /PRNewswire/ --BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biolog...
Leqembi® approved in Mexico
STOCKHOLM , Dec. 4, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) ...
Leqembi® launched in South Korea
STOCKHOLM , Nov. 27, 2024 /PRNewswire/ - BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced today that Leqembi® (generic name: lecanemab) has been launched in South Korea. ...
CHMP issues positive recommendation for approval of lecanemab in the EU
STOCKHOLM , Nov. 14, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommen...
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
STOCKHOLM , Nov. 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs from...
Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
STOCKHOLM , Nov. 6, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) will publish the company's third quarter report for July - September 2024 on Thursday, November 14, 2024, at 08...
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
STOCKHOLM , Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer'...
Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
STOCKHOLM , Oct. 30, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2024, in co...
Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
STOCKHOLM , Oct. 30, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's co-founder, Professor Lars Lannfelt, was awarded the Lifetime Achievement Awar...
Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
STOCKHOLM , Oct. 24, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeuti...
BioArctic AB: The David Against Goliath Of Solving Alzheimer's Disease
BioArctic's (BRCTF) Leqembi, first FDA-approved Alzheimer's drug, faces EMA rejection, but shares could potentially surge soon. See why I rate the stock a Buy.
Eisai will request reconsideration of initial decision for lecanemab in Australia
STOCKHOLM , Oct. 16, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public stat...
Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology
STOCKHOLM , Aug. 27, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the results from two phase-1 studies with exidavnemab have been published in The Journal o...
Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain
STOCKHOLM , Aug. 22, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (brand name, generic name: lecanemab) has been granted Marketing Au...
Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic
STOCKHOLM , Aug. 22, 2024 /PRNewswire/ -- British media are reporting on the imminent approval of lecanemab in Great Britain. BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) has currently not been info...
Invitation to presentation of BioArctic's second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET
STOCKHOLM , Aug. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2024 on Thursday, August 29, 2024, at 08:00 a...
Leqembi approved for the treatment of Alzheimer's disease in the United Arab Emirates
STOCKHOLM , Aug. 13, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) ha...